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Abstract
BACKGROUND: Insufficient vascularization hampers bone tissue engineering strategies for reconstructing large bone
defects. Delivery of prolyl-hydroxylase inhibitors (PHIs) is an interesting approach to upregulate vascular endothelial
growth factor (VEGF) by mimicking hypoxic stabilization of hypoxia-inducible factor-1alpha (HIF-1a). This study
assessed two PHIs: dimethyloxalylglycine (DMOG) and baicalein for their effects on human adipose tissue-derived
mesenchymal stem/stromal cells (AT-MSCs).
METHODS: Isolated AT-MSCs were characterized and treated with PHIs to assess the cellular proliferation response.
Immunostaining and western-blots served to verify the HIF-1a stabilization response. The optimized concentrations for
long-term treatment were tested for their effects on the cell cycle, apoptosis, cytokine secretion, and osteogenic differ-
entiation of AT-MSCs. Gene expression levels were evaluated for alkaline phosphatase (ALPL), bone morphogenetic
protein 2 (BMP2), runt-related transcription factor 2 (RUNX2), vascular endothelial growth factor A (VEGFA), secreted
phosphoprotein 1 (SPP1), and collagen type I alpha 1 (COL1A1). In addition, stemness-related genes Kruppel-like factor 4
(KLF4), Nanog homeobox (NANOG), and octamer-binding transcription factor 4 (OCT4) were assessed.
RESULTS: PHIs stabilized HIF-1a in a dose-dependent manner and showed evident dose- and time dependent antipro-
liferative effects. With doses maintaining proliferation, DMOG and baicalein diminished the effect of osteogenic induction
on the expression of RUNX2, ALPL, and COL1A1, and suppressed the formation of mineralized matrix. Suppressed
osteogenic response of AT-MSCs was accompanied by an upregulation of stemness-related genes.
CONCLUSION: PHIs significantly reduced the osteogenic differentiation of AT-MSCs and rather upregulated stemness-
related genes. PHIs proangiogenic potential should be weighed against their longterm direct inhibitory effects on the
osteogenic differentiation of AT-MSCs.
Keywords Dimethyloxalylglycine  Baicalein  Hypoxia-inducible factor-1alpha  Adipose tissue-derived mesenchymal
stem/stromal cells  Osteogenesis
1 Introduction
Large maxillofacial bone defects are a crippling problem
from functional, psychological, and socioeconomic per-
spectives. Bone tissue engineering is a promising
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alternative to replace autografts and allografts in orthope-
dics and craniomaxillofacial surgery. It has developed
rapidly owing to advances in cell biology and material
science research [1–4].
Adipose tissue has gained much interest as a clinically
appealing source for mesenchymal stem/stromal cells due
to its abundance and accessibility with low donor site
morbidity. Adipose tissue-derived mesenchymal stem/
stromal cells (AT-MSCs) possess a great potential for bone
tissue engineering and regenerative medicine strategies [5].
Such potential is suggested to be mediated through their
immunomodulatory effects, antiapoptotic effects in
osteoblastic lineage cells, recruitment of host stem/pro-
genitor cells, pro-osteogenic effects, and stimulation of
angiogenesis [6]. The proangiogenic role of mesenchymal
stem/stromal cells, which significantly contributes to their
regenerative potential, is mainly exerted via their paracrine
effects which act in a vascular endothelial growth factor
(VEGF)-dependent manner [6–8].
Despite the major advances in the field of tissue engi-
neering, clinical applications remain restricted mainly to
thin or avascular tissues, such as skin, cartilage, and cor-
nea. Larger tissue constructs like bone require a vasculature
that provides the cells with oxygen and nutrients for long-
term survival post-implantation [9–13]. Previous preclini-
cal and clinical trials have focused on enhancing vascu-
larization through the local delivery of VEGF. However,
the short half-life of VEGF reduces its efficacy, and
increasing the dose to super-physiological levels increases
its systemic side-effects and risk of complications [14].
The induction of a therapeutic hypoxic response is an
interesting alternative with clinically relevant potential.
Cells react to low oxygen levels with a hypoxic response,
of which the hypoxia-inducible transcription factor (HIF-1)
is a key regulator [15]. HIF-1 binds hypoxic response
element (HRE)-driven promoters on several genes,
including VEGF, glucose transporter-1, and erythropoietin
[15, 16]. HIF-1 is a heterodimeric complex composed of
HIF-1a and HIF-1b with HIF-1a being the oxygen-regu-
lated subunit [17]. HIF-1a is highly unstable in normoxic
conditions, as it undergoes proteosomal degradation. The
process is initiated by oxygen-dependent hydroxylation of
HIF-1a under the control of prolyl hydroxylases (PHD 1, 2,
and 3) and an asparaginyl hydroxylase known as Factor
Inhibiting HIF-1a (FIH). These hydroxylases require iron,
oxygen, and 2-oxaloglutarate (2-OG) as cofactors for the
hydroxylation process, which in turn leads to Von Hippel-
Lindau protein (pVHL)-mediated ubiquitination and sub-
sequent proteasomal degradation of HIF-1a [18].
Under physical hypoxic conditions, hydroxylase
enzymes are inactive. Prolyl-hydroxylase inhibitors (PHIs)
can mimic the hypoxic response in normoxic conditions by
modulating HIF-1a degradation. Such a chemically-in-
duced hypoxic response occurs in the presence of iron
chelators such as deferoxamine, or in the presence of a
2-OG competitive inhibitors such as dimethyloxalylglycine
(DMOG) [18]. Baicalein is an active flavonoid extracted
from the root of the plant Scutellaria baicalensis, it has
been reported to be a PHD2 inhibitor, which abrogates
asparaginyl hydroxylation of HIF-1 [19].
From the perspective of bone tissue engineering, HIF-1a
stabilization potentially aims at enhancing the proangio-
genic effects of AT-MSCs. Chemical stabilization of HIF-
1a by PHIs could have other effects on AT-MSCs behavior
in the context of bone tissue regeneration. In this study, we
aim to investigate DMOG and baicalein for their effects on
HIF-1a stabilization, proliferation and osteogenic differ-
entiation of AT-MSCs, as potential candidates for targeting
angiogenesis-osteogenesis coupling in bone tissue
engineering.
2 Materials and methods
2.1 Adipose tissue-derived mesenchymal stem/
stromal cells isolation
Water-assisted liposuction-aspirates served as the source of
AT-MSCs. The donors comprised seven females with an
age range of 32–50 (average of 41 ± 7.4), and body mass
index range of 22.7–31.2 (average of 26.4 ± 3.1).
Informed consents were obtained under the ethical
approval of the ethical committee of Helsinki and Uusimaa
Hospital District for the use of adipose tissue in scientific
research. Fresh liposuction-aspirates underwent a combi-
nation of enzymatic and mechanical treatment for the
isolation of AT-MSCs as previously described [20, 21].
Cell cultures were maintained at 37 C and 5% CO2 in a
humidified incubator. The plastic-adherent AT-MSCs were
expanded in maintenance medium (MM) with full medium
change every 3 days, passaging at 1:3 split ratio when 85%
confluent. Cells from passages 3-6 were used in all
experiments. The MM consisted of Dulbecco’s modified
Eagle’s medium/Ham’s Nutrient Mixture F-12 with 1% L-
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alanyl-L-glutamine (DMEM/F-12 1:1 GlutaMAX; ref.
31331-028, Gibco, Grand Island, NY, USA), 1% antibi-
otics (100 U/mL penicillin, 0.1 mg/mL streptomycin; ref.
DE17-602E, Lonza), and 10% fetal bovine serum (FBS;
South American, ref. 10270-106, Gibco).
2.2 Characterization of AT-MSCs
Surface antigens of interest on the AT-MSCs were detected
using a BD Accuri C6 flow cytometer (Becton–Dickinson,
Franklin Lakes, NJ, USA) and allophycocyanin (APC)-
conjugated monoclonal antibodies against CD14 (clone:
M5E2), CD19 (clone: HIB19), CD34 (clone: 581),
CD45RO (clone: UCHL1), CD54 (clone: HA58), CD73
(clone: AD2), CD90 (clone: 5E10), CD105 (clone: 266),
and HLA-DR (clone: G46-6) (BD Pharmingen, Becton-
Dickinson, Franklin Lakes, NJ, USA) [22]. We performed
flow cytometric analysis of AT-MSCs expanded in MM up
to passage 5 using 1 9 104 events recorded per sample.
Expression was considered positive when the level of flu-
orescence was greater than 99% of the corresponding
unstained cell sample [23]. Multipotentiality of AT-MSCs
was assessed by analysing their capacity to differentiate
toward the adipogenic, osteogenic and chondrogenic lin-
eages. The adipogenic differentiation involved culturing
AT-MSCs for 3 weeks in adipogenic media (StemPro
Adipogenesis Differentiation Kit, # A10070-01, Gibco).
Osteogenic differentiation media (OM) consisted of MM
supplemented with 50 lM L-ascorbic acid 2-phosphate,
10 mM b-glycerophosphate disodium salt hydrate, and
5 nM dexamethasone (all from Sigma-Aldrich). Chondro-
genic differentiation was tested in high density spheroid
culture conditions, it was induced by chondrogenic med-
ium consisting of MM with reduced FBS to 1% and sup-
plemented with 1% Insulin-Transferrin-Selenium-
Ethanolamine (ITS-X, # 51500056, Gibco), 50 lg/mL L-
ascorbic acid 2-phosphate (Sigma-Aldrich), 40 lg/mL L-
proline (Sigma-Aldrich), 100 lg/mL sodium pyruvate (#
11360070, Gibco), 100 nM dexamethasone (Sigma-
Aldrich), and 10 ng/mL of TGF-b1 (# 7754-BH-005, R&D
system, Minneapolis, MN, USA).
2.3 Assessing the short-term viability/cytotoxicity
aspects of DMOG and baicalein
Both small-molecule drugs; DMOG (D3695, CAS:
89464-63-1, lot # 086M4731V) and baicalein (465119,
CAS: 491-67-8, lot # MKBV1595V) were from Sigma-
Aldrich (St. Louis, MO, USA). DMOG and baicalein were
readily soluble in DMSO (MP Biomedicals, LLC, Illkirch
Cedex, France). Cell Counting Kit-8 (CCK-8) (# CK04-11,
Dojindo Molecular Technologies, Rockville, MD, Mary-
land, USA) was used according to the manufacturer
instructions to assess the cytotoxicity of varying concen-
trations of DMOG and baicalein, control conditions
received only DMSO in equal volumes. AT-MSCs were
cultured on 96-well plates at 1.6 9 103 cells/well in
100 lL of MM and allowed to attach for 24 h in a
humidified incubator. Cells then received test conditions of
MM with 100, 200, and 500 lM of DMOG, or 5, 10, 50
and 200 lM of baicalein. DMSO in MM (0 lM PHIs)
served as a control condition and wells without cells were
used as blanks. On treatment days 0, 1, and 2 each well
received 10 lL of CCK-8 solution. The absorbance was
measured after 3 h of culture at 450 nm using a microplate
reader (PerkinElmer VICTORTM X4 Multilabel Microplate
Reader 2030, Turku, Finland).
2.4 Assessing DMOG and baicalein effects
on cellular HIF-1a levels
AT-MSCs were seeded in MM at a density of 2 9 104 -
cells/well on sterile coverslip inserts in 24-well culture
plates. After overnight attachment, AT-MSCs were cul-
tured for 5 h in MM with 500 lM DMOG, or 185 lM
baicalein. AT-MSCs cultured in MM with DMSO or
100 lM CoCl26H2O (Merck, Darmstadt, Germany.
Art.2539) served as negative and positive controls,
respectively. Cells were fixed in 4% paraformaldehyde for
10 min and rinsed 3 9 5 min in PBS. Fixed cells were
permeabilized using 0.5% Triton X-100 for 20 min, fol-
lowed by washing in PBS. After blocking in 10% normal
donkey serum for 1 h at RT, cells were incubated overnight
with primary mouse anti-human HIF-1a (# 610959, BD
Biosciences, Franklin Lakes, NJ, USA) at a dilution of 1:50
in 0.5% normal donkey serum at 4 C. Coverslips were
rinsed, then incubated with both donkey anti-Mouse IgG
secondary antibody (Alexa Fluor 568, # A10037, Life
Technologies, Eugene, OR, USA) in 5 lg/ml dilution and
CellTraceTM 1:1000 (CFSE Cell Proliferation Kit, #
C34554, Life technologies) for 1 h at RT. Nuclei were
stained in Hoechst 33342 (# B2261, Sigma-Aldrich) for
30 min in the dark, followed by washing and mounting on
a glass slide with SlowFade mountant (# S36967, Thermo
Fisher Scientific, Waltham, MA, USA). We used a Leica
TCS SP8 confocal microscope (Leica Microsystems
GmbH, Wetzlar, Germany) to image the cells.
2.5 Western blotting for HIF-1a and VEGF
AT-MSCs seeded at a density of 3 9 105 cells/well in
6-well culture plates were cultured for 5 h in MM with
500 lM DMOG or 185 lM baicalein. MM with DMSO or
100 lM CoCl26H2O (Merck, Art. 2539) served as nega-
tive and positive controls, respectively. AT-MSCs were
lysed with 1 9 cell lysis buffer (# 9803, Cell Signaling
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Technology). After measuring protein concentrations, by
PierceTM BCA Protein Assay Kit (# 23227, Thermo Fisher
Scientific), samples containing 22 lg protein were dena-
tured at 95 C for 5 min in reducing Laemmli sample
buffer, separated using Mini-PROTEAN TGXTM 12%
gradient SDS-PAGE gel (Bio-Rad, Hercules, CA, USA)
with BlueSTAR prestained protein marker (# MWP03,
Nippon Genetics Europe GmbH) as a standard. Running
conditions were 150 V for 60 min. Blotting involved semi-
dry transfer of proteins on nitrocellulose membranes of
0.2 lm pore size (#162-0112, Bio-Rad), using 40 mA per
gel for 60 min.
For normalizing the target signal, we utilized
REVERTTM Total Protein Stain kit (# 926-11010, LI-COR,
Lincoln, NE, USA) according to manufacturer’s instruc-
tions. Blocking and antibody incubations were performed
in Odyssey blocking buffer (LI-COR) without and with
0.1% Tween-20, respectively. Primary antibodies of mouse
anti-human HIF-1a (1:500, # 610959, BD Biosciences) and
VEGF antibody (C-1) (1:200, # sc-7269, Santa Cruz,
Dallas, TX, USA) were used for immunodetection. After
primary antibody overnight incubation at ? 4 C, mem-
branes were washed in TBS-T and probed with secondary
IRDye 800CW Goat (LI-COR) at 1: 15,000 for 1 h at RT.
Odyssey FC Imager (LI-COR) and Image StudioTM Soft-
ware served to quantify the lane normalization factor and
normalizing the immunodetected-signal.
2.6 HIF-1a stabilization response for DMOG
and baicalein doses
AT-MSCs were plated in black 96-well clear-bottom plates
(# 6005182, Perkin-Elmer) at a cell-density of 1 9 104 -
cells/well and allowed to adhere overnight. Cells were
cultured for 5 and 72 h in MM with 312.5, 625, and
1563 lM of DMOG, or 16, 32, 162, and 624 lM of bai-
calein, or with equal volumes of DMSO. The HIF-1a sta-
bilization was quantified using the In-Cell ELISA Near
Infrared Detection Kit (# 62201, Thermo Fisher Scientific)
following the manufacturer’s instructions. Cells were fixed
in 4% methanol-free formaldehyde (# 28906, Thermo
Scientific), followed by washing, permeabilization, and
blocking steps. HIF-1a was probed using mouse anti-hu-
man HIF-1a (1:50, # 610959, BD Biosciences), and an
antibody for housekeeping protein rabbit polyclonal beta
actin (2 lg/mL, # PA5-16914, Thermo Fisher Scientific).
After overnight incubation at ? 4 C, AT-MSCs were
washed with 1 9 wash buffer before incubation with spe-
cies-specific near-infrared DyLight-conjugated secondary
antibody mix for 1 h at RT. After washing steps, Odyssey
FC Imager (LI-COR) served to scan the plates with exci-
tation/emission maxima of 692/712 nm for DyLight 680
Dye and 777/794 nm for DyLight 800 Dye. Measured
signals were analyzed with Image Studio Software (LI-
COR).
2.7 Assessing the long-term viability/cytotoxicity
aspects of DMOG and baicalein
Viability/cytotoxicity responses over prolonged exposure
to PHIs was assessed using CCK-8 assay and
CyQUANTTM Cell Proliferation Assay Kit (# C7026,
Invitrogen). AT-MSCs were seeded at a density of
1.6 9 103 cells/well in 96-well plate and 100 lL of MM
per well was added containing 100, 200, and 500 lM of
DMOG, or 5, 10, 50, and 200 lM of baicalein. Cell via-
bility was either assayed using the CCK-8 assay following
manufacturer’s protocol at 0, 3, 6, 10, and 14 days of
treatment, or cells were lysed in 0.1% Triton-X 100
(Sigma-Aldrich) after 0, 1, 3, 7, and 14 days of treatment.
A freeze–thaw cycle assisted cell lysis prior to analysis.
CyQUANTTM cell proliferation assay kit was used to
estimate the total cellular DNA in cell lysates. Fluores-
cence was measured with VICTORTM microplate reader at
480/520 nm excitation/emission maxima. Proliferation
assays were used for estimating the optimized PHIs con-
centrations for long-term treatment of AT-MSCs.
2.8 Cell cycle analysis and Annexin V/PI Flow
cytometric assay
The optimized PHIs concentrations were 3.75 pmol/cell of
DMOG and 0.25 pmol/cell for baicalein. These concen-
trations were assessed with regards to their effects on the
cell cycle and apoptosis of AT-MSCs after 4 days and
14 days of treatment. For cell cycle analysis, harvested
ethanol-fixed cells were stained with FxCycleTM PI/RNase
Staining Solution (# F10797, Thermo Fisher Scientific)
according to the manufacturer’s protocol, then underwent
flow cytometry using BD Accuri C6 flow cytometer. For
apoptosis assay, harvested cells were washed and stained
using Dead Cell Apoptosis Kit with Annexin V Alexa
FluorTM 488 and Propidium Iodide (PI) (# V13241,
Thermo Fisher Scientific) according to the manufacturer’s
protocol, followed by flow cytometric analysis using BD
Accuri C6.
2.9 Human cytokine antibody assay for AT-MSCs
conditioned media
AT-MSCs were seeded in 48-well plates at a density of
1 9 104 cells/well. The AT-MSCs were cultured in
300 lL/well of MM or OM supplemented with
3.75 pmol/cell of DMOG, 0.25 pmol/cell baicalein, or
equal volumes of DMSO. After 14 days of treatment, cells
were cultured in serum-free medium for 24 h. Conditioned
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medium was collected and centrifuged (1000g for 10 min,
? 4 C). The supernatant was stored in - 80 C until
further analysis. Levels of secreted cytokines of interest
were measured using human cytokine antibody array
membranes (# ab133998, Abcam, Cambridge, UK) fol-
lowing the manufacturer’s protocol. Briefly, membranes
were incubated in blocking buffer (30 min, RT). Equal
amounts of proteins were pooled from three independent
experiments to achieve the same protein concentration in
all samples. Samples were incubated overnight on mem-
branes at ?4 C under gentle shaking. Thorough washing
steps of membranes preceded incubation at with biotin-
conjugated anticytokines. Membranes were washed thor-
oughly and incubated with HRP-conjugated streptavidin
overnight at ?4 C. After washing, the membranes were
blot-dried and incubated with the detection buffer for
2 min at RT and were then imaged using ChemiDoc XRS
Imaging System (Bio-Rad). ImageJ software (National
Institutes of Health) was used to quantify the intensity of
individual dots by densitometric analysis. MM with DMSO
served as reference, and normalized signal density of each
dot was then calculated. Due to the low number of negative
controls; 2 per membrane, the background error was esti-
mated by taking the difference between the average of
negative controls and the lowest value on the assay. Only
cytokines detected above experimental error in at least one
sample were included in the analysis.
2.10 Biochemical analyses for osteogenic response
The osteogenic potential of AT-MSCs was assessed under
the concentrations and experimental setting described in
Sect. 2.9 using alkaline phosphatase (ALP) assay,
hydroxyproline assay, and Alizarin Red S stain (ARS) after
14 days of treatment. In order to assess the effect of col-
lagen-I on mineralization response of AT-MSCs by ARS,
culture was repeated on plates coated with Rat tail colla-
gen-I (# 354236, CORNINGTM, Corning, NY, USA)
according to manufacturer’s instructions. AT-MSCs were
lysed using 0.1% triton-x-100 and freezing at - 80 C.
Alkaline phosphatase activity was measured by mixing the
cell lysate with p-nitrophenyl phosphate disodium (#
P5744, Sigma-Aldrich) and 2-amino-2-methyl-1-propanol
(# A9226, Sigma-Aldrich). The amount of produced p-ni-
trophenol was measured in microplate reader at 405 nm.
Hydroxyproline assay Kit (# MAK008, Sigma-Aldrich)
was employed according to the manufacturer’s protocol to
determine the hydroxyproline concentration in cell lysates,
correlating with the collagen content. Briefly, after
hydrolyzing cell lysates in 6 N hydrochloric acid at 120 C
for 3 h, oxidized hydroxyproline was allowed to react with
4-(dimethylamino) benzaldehyde for 90 min at 60 C.
Absorbance of the colorimetric product was measured at
550 nm in the microplate reader. To normalize the alkaline
phosphate activity and total collagen content for cell
number, the amount of DNA in the cell culture lysates was
quantified using CyQUANTTM cell proliferation assay.
For Alizarin Red S Staining (ARS), AT-MSCs were
fixed in ice-cold 70% ethanol for 1 h at RT, followed by
rinsing twice with ddH2O. Cells were stained with 2%
ARS solution (# A5533-25G, Sigma-Aldrich) for 30 min at
RT, followed by thorough washing for 5 9 5 min in fresh
ddH2O under shaking. Bound ARS was extracted using
100 mM N-cetylpyridinium chloride monohydrate (Mer-
ck) in ddH2O for 2 h in 37 C followed by measuring the
eluted stain at 550 nm in the microplate reader. To nor-
malize the ARS/cell, fixed cells were stained by 2 mM
Janus Green B Stain (# 201677-25G, Sigma-Aldrich) for
5 min at RT. After washing for 5 9 5 min in fresh ddH2O,
0.1 mL 0.5 M HCL was added per well and left for 10 min
to elute the stain. This was followed by shaking the plate
for 10 s and measuring the absorbance at 550 nm in the
microplate reader.
2.11 Gene expression analyses by quantitative PCR
(qRT-PCR)
We analyzed gene expression by AT-MSCs at 7 days of
treatment. Total RNA was isolated using the miRCURYTM
RNA Isolation Kit (Exiqon A/S) according to the manu-
facturer’s instructions. Reverse transcription into cDNA
was done using a SuperScriptTM IV VILOTM reaction
mixture (# 11766050, Thermo Fisher Scientific). PCR
reactions were conducted on a QuantStudioTM 5 Real-Time
PCR System (Thermo Fisher Scientific) using TaqMan
assays (Thermo Fisher Scientific) for the following genes:
alkaline phosphatase, liver/bone/kidney (ALPL, assay ID
Hs01029144_m1), bone morphogenetic protein 2 (BMP2,
assay ID Hs00154192_m1), runt-related transcription fac-
tor 2 (RUNX2, assay ID Hs01047973_m1), vascular
endothelial growth factor A (VEGFA, assay ID
Hs00900055_m1), secreted phosphoprotein 1 (SPP1, assay
ID Hs00959010_m1), collagen type I alpha 1 (COL1A1,
assay ID Hs00164004_m1), and ribosomal protein lateral
stalk subunit P0 (RPLP0, assay ID Hs99999902_m1) as a
house keeping gene for normalization.
Stemness-related genes Kruppel-like factor 4 (KLF4),
Nanog homeobox (NANOG), and octamer-binding tran-
scription factor 4 (OCT4) were assessed using primers at
2 lM concentration (Table 1), and 5 9 HOT FIREPol
EvaGreen qPCR Mix Plus (no ROX) (# 08-25-00001, Solis
BioDyne, Tartu, Estonia) in a final volume of 20 lL and
run in Rotor-Gene Q (Qiagen, Hilden, Germany). Cyclo-
philin G (CycloG) served as an endogenous housekeeping
control gene for stemness-related genes. Data were
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analyzed using the 2-DDCt method to quantify relative gene
expression [24].
2.12 Statistical analysis
Statistical analyses were performed using arithmetic mean
of at least three technical replicates from three AT-MSCs
donors (biological replicates) by Origin 2018 (OriginLab,
Northampton, MA, USA). Analysis of variance (ANOVA)
was employed; either one-way or two-way depending on
independent variables. Bonferroni-corrected post hoc
means comparison tests were performed to analyze specific
sample pairs for significant differences. The results were
considered significant when p\ 0.05.
3 Results
3.1 AT-MSCs characterization
AT-MSCs showed the characteristics defined by the
International Federation for Adipose Therapeutics (IFATS)
Table 1 Primers used for assessing stemness-related genes
Genes Sequence of 50-primer (F) Sequence of 30-primer (R) Size (bp) Origin
KLF4 50-CCGCTCCATTACCAAG-30 50-CACGATCGTCTTCCCCTCTT-30 80 hum (NM_004235.4)
NANOG 50-CTCAGCCTCCAGCAGATGC-30 50-TAGATTTCATTCTCTGGTTCTGG-30 94 hum (NM_024865.2)
OCT4 50-TTGGGCTCGAGAAGGATGTG-30 50-TCCTCTCGTTGTGCATAGTCG-30 91 hum (NM_002701)
CycloG 50-TCTTGTCAATGGCCAACAGAG-30 50-GCCCATCTAAATGAGGAGTTG-30 84 hum (NM_004792)
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Fig. 1 AT-MSCs characterization; A Surface markers’ expression of
undifferentiated AT-MSCs cultured in MM as analyzed by flow
cytometry. Empty histograms show signal from unstained control
cells, while grey-filled histograms show signal of cells stained with
antibody against the surface proteins. B A column graph shows mean
and SD for surface marker expression levels (%) of undifferentiated
AT-MSCs (n = 7). C Photomicrographs show multipotentiality of
tested AT-MSCs when induced for 3 weeks towards adipogenesis
(Oil Red O staining; upper row), osteogenesis (Alizarin Red S
staining; middle row), and chondrogenesis (Toluidine blue staining;
lower row). Maintenance medium (MM) was used in parallel as a
negative control for differentiation conditions. Scale bar = 200 lm
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and Science and the International Society for Cellular
Therapy (ISCT) [22, 25]. The plastic-adherent AT-MSCs
had fibroblast-like morphology, expressed surface markers
CD73, CD90 and CD105, while lacking the expression of
hematopoietic markers CD14, CD19, CD45 and HLA-DR
(Fig. 1A). The cells showed a moderate expression of
CD34 and evident donor variability in the expression of
CD34 and CD54 (Fig. 1B).
AT-MSCs showed the capacity for adipogenic differ-
entiation with gradual accumulation of lipid intracellular
droplets, detected by Oil Red O stain (Fig. 1C). Osteogenic
differentiation under described induction condition was
successful (Fig. 1C and supplementary Fig. 3). The chon-
drogenic differentiation for AT-MSCs spheroids was
assessed by Toluidine blue staining which showed a purple
metachromatic stain confirming the presence of extracel-
lular glycosaminoglycans when cells were cultured in
chondrogenic induction medium (Fig. 1C).
3.2 Short-term viability/cytotoxicity aspects
of DMOG and baicalein
AT-MSCs viability declined with 500 lM of DMOG on
the second day of treatment as compared to control con-
dition but the difference was not significant (Fig. 2A).
Although cellular viability relatively decreased with bai-
calein treatment as compared to control, the difference was
non-significant (Fig. 2B). These results reveal that con-
centrations up to 500 lM DMOG and 200 lM baicalein
are suitable for short-term treatment of AT-MSCs.
3.3 DMOG and baicalein stabilize HIF-1a in AT-
MSCs
Immunostaining revealed the localization of HIF-1a in the
nuclei of cells treated with DMOG and baicalein. This
confirmed the ability of both tested drugs to stabilize cel-
lular HIF-1a, which mainly translocated into the nucleus
(Fig. 3A–D). Western blotting also confirmed stabilized
HIF-1a and VEGF expression in treated samples as well as
in positive controls, although variability in donor response
was evident (Fig. 3E–G). Both tested drugs stabilized HIF-
1a in a dose dependent manner, DMOG showed higher
potency to stabilize HIF-1a, the response to DMOG rapidly
declined, whereas the lower HIF-1a stabilization effect of
baicalein did not show significant decrease overtime
(Fig. 4).
3.4 Long-term viability/cytotoxicity aspects
of DMOG and baicalein
CCK-8 results showed a significant effect of DMOG on
cell viability for drug concentration (F (3, 40) = 148.9,
p\ 0.0001), for the duration of treatment (F (4,
40) = 33.9, p = 2.3 9 10-12), and a significant interaction
(F (12, 40) = 17.9, p = 1.9 9 10-12). The cell viability
significantly deteriorated with 500 lm DMOG on the third
day of treatment (Fig. 5A). Baicalein showed a significant
main effect for drug concentration (F (4, 50) = 189.5,
p\ 0.0001), for the duration of treatment (F (4,
50) = 50.9, p\ 0.0001), and a significant interaction
(F (16, 50) = 21.8, p\ 0.0001). Cytotoxicity of baicalein
started to be significant on the third day with 50 lM and
200 lM baicalein (Fig. 5B). A dose–response curve, for
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Fig. 2 Short-term viability of AT-MSCs in presence of DMOG
(A) and baicalein (B); CCK-8 assay results for AT-MSCs cultured for
2 days in presence of various concentrations of DMOG (A) and
baicalein (B). 0 lM is MM ? DMSO. Column graphs represent mean
and SD for three independent biological replicates (dots)
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the CCK-8 results on third day, was used to estimate the
optimized concentrations for long-term treatment of AT-
MSCs corresponding to a viability percentage of 70%
(Fig. 5C). We found it more reproducible to express con-
centrations in moles per cell [26]. Optimized concentra-
tions were 3.75 pmol/cell of DMOG and 0.25 pmol/cell of
baicalein (Fig. 5C). Total DNA content measurements
were in line with CCK-8 results; however, significant
cytotoxicity was evident only after 3 days (Fig. 5D, E).
These findings suggest an earlier effect on the metabolic
activity of the cells, which was evident at the third day.
Cell cycle analysis of AT-MSCs treated with optimized
concentrations of PHIs revealed, in both treatment dura-
tions, that PHIs moderately increased the percentage of
cells in G2/M phase at the expense of G0/G1 phase
(Fig. 6A–H). Annexin V/PI flow cytometric analysis
results, did not show a significant cellular apoptosis or
necrosis at tested concentrations for both durations as
compared to DMSO control (Fig. 6I–N).
3.5 DMOG and baicalein attenuated the osteogenic
potential of AT-MSCs
AT-MSCs showed an osteogenic response at 14 days of
treatment exclusively with OM ? DMSO, whereas tested
PHIs attenuated osteogenic induction (Fig. 7). One-way
analysis of variance for ALP assay results showed that
average relative ALP activity for OM ? DMSO was sig-
nificantly higher (p\ 0.001) than all other test conditions,
adding PHIs to OM reduced ALP activity (Fig. 7A). Rel-
ative collagen content, as estimated by hydroxyproline
assays, showed a significantly higher collagen content in
OM ? DMSO than in the other test conditions (p\ 0.05)
(Fig. 7B). The ARS assay results also showed that average
relative mineralization for OM ? DMSO was significantly
higher (p\ 0.001) than all other test conditions (Fig. 7C),
whereas adding PHIs to OM significantly reduced the rel-
ative mineralization. Collagen coating of the plates did not
enhance mineralization (Fig. 7D).
3.6 Cytokine analysis for AT-MSCs conditioned
media
Out of the 80 cytokines included in the cytokine array 75
were detected in at least one sample. Unsupervised clus-
tering analysis (Fig. 8A) showed that DMOG and baicalein
had distinctive effects on cytokine levels, and their effects
differed in MM and OM. Similar effects were observed for
baicalein and DMOG, especially in angiogenesis-related
cytokines (Fig. 8B). Both DMOG and baicalein increased
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Fig. 3 DMOG and baicalein stabilize HIF-1a in AT-MSCs; confocal
microscopy images for HIF-1a immunostained samples of AT-MSCs
treated with MM ? DMSO (A) as a negative control,
MM ? CoCl2.6H2O as a positive control (B), MM ? DMOG (C),
and MM ? Baicalein (D). Stabilized HIF-1a translocated into the
nuclei in all conditions except negative control. Western blotting of
HIF-1a and VEGF (E), and band density analysis normalized to total
protein stain (REVERTTM) (F, G). Both drugs as well as positive
control stabilized HIF-1a and increased VEGF levels. Column graph
represents mean and SE for three biological replicates (dots); Scale
bar 50 lm
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VEGF and platelet-derived growth factor-BB (PDGF-BB)
levels in OM and MM media. However, DMOG decreased
the concentration of several CC chemokines, such as
macrophage inflammatory protein-1b (MIP-1b), macro-
phage-derived chemokine (MDC), eotaxin, and CXC
chemokines like growth regulated a protein (GRO-a) and
granulocyte chemotactic protein 2 (GCP-2). Baicalein
instead increased levels of stem cell factor (SCF), macro-
phage inflammatory protein-3 (MIP-3a), and transforming
growth factor-beta 2 (TGF-b2) in both MM and OM, and
increased the concentration of transforming growth factor-
beta 3 (TGF-b3) and osteopontin in OM.
3.7 Quantitative PCR (qRT-PCR) results
DMOG upregulated VEGFA expression more than baica-
lein (Fig. 9A). Gene expression of RUNX2 showed largest
differences between the means of test conditions and
OM ? DMSO. However, due to variability in donor
response, a significant difference was not detected
(Fig. 9B). Tested conditions did not significantly alter
ALPL gene expression except for OM ? DMSO which
significantly increased ALPL gene expression (Fig. 9C).
COL1A1 gene expression and hydroxyproline content also
followed similar trends (Fig. 7B). However, variability in
donor responses resulted in only slightly non-significant
differences (p = 0.07) (Fig. 9D). BMP2 relative gene
expression levels showed the largest difference in means
between OM ? baicalein and OM ? DMSO (Fig. 9E).
Gene expression SPP1 increased in the presence of bai-
calein, especially in MM (Fig. 9F). Both PHIs upregulated
stemness markers KLF4, NANOG, and OCT4, with a sig-
nificant upregulation trend especially under osteogenic
induction (Fig. 10A–C).
4 Discussion
In this study we show that tested PHIs can potentially
enhance the proangiogenic effects of AT-MSCs in bone
engineering strategies via HIF-1a/VEGF pathway. Long-
term PHIs treatment, however, can reduce the osteogenic
potential of AT-MSCs and rather upregulate stemness
markers.
Enhancing vascularization of tissue engineered bone
substitutes is crucial for maintaining the cellular oxy-
genation, nutrition, waste removal, and for recruiting
osteoprogenitors and immune cells. Albeit angiogenesis
and osteogenesis are different processes; they are never-
theless, critically orchestrated in a series of events during
bone development and regeneration process [27].
Both tested PHIs were able to stabilize HIF-1a in a
dose-dependent manner, although their stabilization
responses were distinct. DMOG and baicalein slowed down
proliferation of AT-MSCs in a dose and time dependent
manner. Ding and coworkers reported a similar effect of
DMOG on AT-MSCs from rats [28]. On the other hand,
Marchbank and coworkers showed that DMOG induced a
dose-dependent increase in proliferation in human stomach
and colonic carcinoma cells with maximal response seen at
a concentration of 70 lM. Whereas, at 70–120 lM DMOG
inhibited cell proliferation [29]. Baicalein has been
BA
Fig. 4 HIF-1a stabilization response in different doses overtime; In-
Cell ELISA assay results showing dose-dependent stabilization of
HIF-1a by DMOG and baicalein at 5 h. A After 72 h, HIF-1a levels
declined significantly with DMOG (B). The line graph in A shows
three donors’ mean (line) ± SE (dotted lines) response for tested drug
concentrations expressed in pM/cell. Column graph in B shows
observed mean and SE for three independent biological replicates
(Symbols; D and O), horizontal dashed reference line denotes relative
signal of control condition (MM ? DMSO), *p B 0.05;
****p B 0.0001
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reported to have antiproliferative effects on human col-
orectal cancer cells and hepatocellular carcinoma cell lines
[30, 31]. The use of initial concentrations from the short-
term cytotoxicity assays for treating AT-MSCs under
osteogenic induction suggested a considerable effect of
treatment duration on cell viability (data not shown). Such
findings required setting up a viability dose–response for
AT-MSCs upon treatment with tested drugs for a longer
time period (14 days). We emphasized the importance of
integrating different physical parameters of the experiment
in effective drug concentration calculation, e.g., cell-
seeding density, plate well-size, and volume of the media.
This was feasible by considering the PHIs concentrations in
mole/cell. Expressing drug doses this way improves
translatability of experiments between labs as was sug-
gested by Doskey et al. [26].
Hypoxic response effects on cellular proliferation are
largely dependent on oxygen levels as well as the duration
of hypoxia [32, 33]. In our study, we showed the impact of
the hypoxia-mimicking agents’ concentration and duration
of treatment on cellular proliferation. Therefore, we
focused on developing a methodology to target a concen-
tration-window that achieved the desired proangiogenic
signaling while maintaining the cellular proliferation
capacity even during prolonged exposure to the tested
PHIs. The optimized concentrations for long-term treat-
ment of AT-MSCs were estimated based on the accepted
relative viability percentage of 70% [34, 35]. Verification
of the suitability of the optimized concentrations also
involved cell cycle analysis and apoptosis assay. The
results did not show significant cellular apoptosis or
necrosis at tested concentrations, however, cell cycle
analysis showed a trend towards increased G2/M phase,
which does not necessarily imply cell cycle arrest, but
rather infer a delay or slow-down in the cell cycle due to
the repair mechanisms that block the entry of the cells into
mitosis.
HIF-1a/VEGF pathway is critical for coupling angio-
genesis and osteogenesis during both skeletal development
and postnatal bone regeneration [27, 36, 37]. However, the
effects of HIF-1a pathway targeting on osteoblasts and
osteoprogenitors are disputed. Previous studies have
demonstrated hypoxia to exhibit no or even negative
effects on osteogenesis by osteogenically-induced bone
marrow-derived mesenchymal stem cells (BMSCs) and
osteoblasts [33, 38–41]. On the other hand, other studies
have reported that BMSCs undergo osteogenic differenti-
ation in response to hypoxia [42]. Wagegg and coworkers
showed that hypoxia promoted osteogenesis of human
BMSCs and chemically-induced hypoxia had nearly simi-
lar effect when agents were applied once weekly [43]. We
see the large heterogeneity in treatment duration and
experimental settings behind the contradicting reports.
In our hands, DMOG abolished the effects of osteogenic
induction of AT-MSCs, based on gene expression levels
and matrix formation. Other research groups have found
that treatment with DMOG can stimulate osteogenic and
angiogenic differentiation of human BMSCs [44, 45]. The
observed difference might be attributed to differences in
the cell source, state of differentiation, duration of treat-
ment, or applied effective concentrations. Baicalein atten-
uated the osteogenic induction on matrix formation, despite
overexpressed BMP2 and SPP1 genes, and increased levels
of osteogenic cytokines such as PDGF-BB, TGF-b2, TGF-
b3, and osteopontin. Tested PHIs showed the same effect
on osteogenic potential of AT-MSCs even at lower con-
centrations (Supplementary Fig. 4).
Cobalt chloride (CoCl2) is a recognized chemical
inducer of hypoxic response in cell culture [46, 47]. Using
CoCl2 to treat AT-MSCs, in the same experimental pro-
tocol of this study, revealed a similar effect of CoCl2, like
tested PHIs, on cellular proliferation and osteogenic
potential of AT-MSCs (supplementary Figs. 5 and 6). Such
findings indicate a common effect of the prolonged
chemically-induced hypoxia; with tested PHIs and CoCl2,
on the proliferation and osteogenic differentiation of AT-
MSCs.
Interestingly, both PHIs upregulated stemness markers
KLF4, NANOG, and OCT4. Such findings are in accor-
dance with Menon and coworkers, who described a similar
effect of DMOG on human tendon stem cells [48]. In
another setting, we found that such trend held true upon the
treatment of AT-MSCs with PHIs for successive passages
in regular culturing media. The observed overexpression of
OCT4 and NANOG in the higher passages implies a clear
effect of the long-term exposure to PHIs, as AT-MSCs
seemed to adapt to the hypoxic response by maintaining
their stemness as well as proliferative capacity, as previ-
ously reported [49]. In accordance with the cell cycle
analysis and apoptosis assay results, the tested
bFig. 5 Long-term viability of AT-MSCs in presence of DMOG and
baicalein; results of CCK-8 assay for cellular proliferation and
metabolic activity (A, B) and CyQUANT assay for DNA content (D,
E) up to 14 days of treatment. Significant deterioration of cellular
proliferation and metabolic activity was detected prior to the
reduction in DNA content. Earliest significant cytostatic/cytotoxic
effects were detected with CCK-8 on the third day, these results were
employed to develop a cell viability-concentration curve (C) in which
cell viability is expressed as relative to the control. The line graph in
C shows mean (line) ± SE (dotted lines) relative viability at tested
drug concentrations; horizontal dashed reference line denotes the
aimed 70% viability level; corresponding drug concentrations were
employed in subsequent analyses. Column graphs show observed
mean and SD for three independent biological replicates (dots),
*p B 0.05 compared to 0 lM (MM ? DMSO) control
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concentrations of PHIs did not cause cell cycle arrest as
evidenced by the repeated passaging of the AT-MSCs
under continuous exposure to PHIs (supplementary Fig. 7).
The effects of the tested chemicals on the cell cycle and
osteogenic differentiation could also involve a role of the
upregulated OCT4 gene, as revealed by qRT-PCR. OCT4
has been suggested to promote G1/S transition and reduce
differentiation, while also controlling cell cycle regulators
to ensure a proper duration of G2 for checking genome
integrity and decreasing chromosomal mis-segregation
[50, 51]. The prolonged chemically-induced hypoxic
response could therefore have helped the AT-MSCs adapt
for maintaining their stemness as well as proliferative
capacity.
HIF-1a has been proposed having an inhibitory effect on
Wnt/b-catenin pathway, this inhibition has been shown to
be at least partially due to the HIF-1a-mediated activation
of the Wnt antagonist sclerostin (SOST) [52]. Interestingly,
we found a similar trend for SOST upregulation, especially
bFig. 6 Cell cycle analysis and Annexin V/PI flow cytometric assay
results; cell cycle representative histograms of the gated cells after
4 days (A–C) and 14 days of treatment with PHIs (E–G). Quantita-
tive analysis of distribution of the cells in each phase was performed
from at least 10,000 cells per sample after 4 days (D) and 14 days of
treatment (H). Annexin V/PI flow cytometric analysis for AT-MSCs
treated with PHIs for 4 days (J, K) and 14 days (M, N), as compared
to control cells treated with DMSO (I, L). The results did not show a
significant cellular apoptosis or necrosis at tested concentrations for
both durations as compared to DMSO control. Column graphs show
observed mean and SD for three independent biological replicates
(dots). *p\ 0.05 versus control
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Fig. 7 DMOG and baicalein attenuated AT-MSCs osteogenic induc-
tion; quantified normalized ALP activity (A), collagen content (B),
and mineralization content (C, D). Both drugs significantly reduced
the osteogenic response of cells to levels comparable to their non-
osteogenic induction counterparts (A–C), mineralization ARS assay
showed similar finding even with collagen-I precoated plates (D).
Column graphs show observed mean and SD for three independent
biological replicates (dots), *p\ 0.05 compared to other conditions
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with DMOG treatment (supplementary Fig. 8), which
could be associated with the HIF-1a stabilization effect and
suggest a possible mechanism for the attenuated osteogenic
response.
In conclusion, our results show that prolonged HIF-1a
activation in AT-MSCs inhibited their osteogenic differ-
entiation and directed them towards stemness. Such
bFig. 8 Cytokine array analysis results; showing unsupervised clus-
tering analysis of all the detected cytokines (A) and relative change in
concentration of 12 most significant cytokines induced by baicalein
and DMOG (B). In B, cytokines are grouped in three groups:
Top = change of concentration levels in both maintenance media
(MM) and osteogenic media (OM), middle = change of concentration
levels only in OM, bottom = change of concentration levels only in
MM
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Fig. 9 Expression of VEGFA and osteogenic genes in response to
PHIs in both maintenance and osteogenic induction conditions; after
1 week of treatment, VEGFA (A) was upregulated with DMOG and to
a lower extent with baicalein in both MM and OM. Relative gene
expression levels for RUNX2 (B), ALPL (C), and COL1A1
(D) declined with both DMOG and baicalein. Baicalein revealed a
trend for upregulating BMP2 and SPP1 (E, F). Column graphs show
observed mean and SD for three independent biological replicates
(dots), *p\ 0.05
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Fig. 10 DMOG and baicalein upregulated stemness markers; relative
gene expression levels for KLF4 (A), NANOG (B), and OCT4
(C) showed an upregulation trend with both PHIs, which was
significantly evident with osteogenic induction for KLF4 and
NANOG. Column graphs show observed mean and SD for three
independent biological replicates (dots), *p\ 0.05
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findings suggest an intimate correlation between stemness
and prolonged hypoxic response, potentially simulating the
hypoxic niches of MSCs, where they maintain their stem-
ness and self-renewal properties. Despite the reduced
osteogenic potential, PHIs-treated AT-MSCs showed
enhanced proangiogenic properties, while maintaining their
stemness. This can be advantageous for improving AT-
MSCs survival and engraftment in vivo, and for boosting
their regenerative potential which should be explored in
future in vivo experiments.
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